Johnson & Johnson

Johnson & Johnson has announced its plans to acquire Neostrata, its affiliates and Tristrata Incorporated.

The acquisition enables Johnson & Johnson and Neostrata to discover and develop new important skincare solutions associated with human insights and compelling science.

DNA2.0 has announced its plans to develop protein pharmaceutical research by employing unparalleled antibody production and engineering platform through acquisition of MIGS’s assets.

Pursuant to the transaction, Michael Feldhaus, the co-founder of MIGS, will join DNA2.0 team as senior vice-president of antibody technologies in Newark, California.

Image: Johnson & Johnson has announced its plans to acquire Neostrata; Photo: courtesy of Luis Gracia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.